Agomelatine in generalized anxiety disorder: An active comparator and placebo-controlled study

Journal of Clinical Psychiatry

Volumn 75, Issue 4, 2014, Pages 362-368

  Stein, Dan J ^a   Ahokas, Antti ^b   Márquez, Miguel S ^c   Häschl, Cyril ^d   Oh, Kang Seob ^e   Jarema, Marek ^f   Avedisova, Alla S ^g   Albarran, Cristina ^h   Olivier, Valérie ^h  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b Mehilainen Oy   (Finland)

^c ADINEU (Assistance Teaching and Research in Neuroscience)   (Argentina)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

^e Sungkyunkwan University School of Medicine   (South Korea)

^f INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^g Laboratory of Immunochemistry   (Russian Federation)

^h IRIS Institut de Recherches Internationales Servier   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; AMINOTRANSFERASE; ESCITALOPRAM; PLACEBO;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECZEMA; EDEMA; FEMALE; FUNCTIONAL STATUS; GASTROINTESTINAL DISEASE; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HEADACHE; HUMAN; HYPEREMIA; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PANIC; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINOPHARYNGITIS; SLEEP QUALITY; SOMNOLENCE; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VERTIGO;

ACETAMIDES; ADOLESCENT; ADULT; AGED; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; CITALOPRAM; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84899761273     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.13m08433     Document Type: Article

References (40)

1. Hoffman DL, Dukes EM, Wittchen HU. Human and economic burden of generalized anxiety disorder. Depress Anxiety. 2008;25(1):72-90.
2. Kessler RC, Berglund PA, Dewit DJ, et al. Distinguishing generalized anxiety disorder from major depression: Prevalence and impairment from current pure and comorbid disorders in the US and Ontario. IntJMethods Psychiatr Res. 2002;11(3):99-111.
3. Kessler RC, Brandenburg N, Lane M, et al. Rethinking the duration requirement for generalized anxiety disorder: Evidence from the National Comorbidity Survey Replication. Psychol Med. 2005;35(7) :1073-1082.
4. Wittchen HU. Generalized anxiety disorder: Prevalence, burden, and cost to society. Depress Anxiety. 2002;16(4):162-171.
5. Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Em-ope 2010. EurNeuropsychopharmacol. 2011;21(9):655-679.
6. Bandelow B, Zohar J, Hollander E, et al; WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive Compulsive and Post Traumatic Stress Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive compulsive and post traumatic stress disorders first revision. World I Biol Psychiatry. 2008;9(4):248-312.
7. Baldwin DS, Waldman S, Allgulander C. Evidence based pharmacological treatment of generalized anxiety disorder. IntJNeuropsychopharmacol. 2011;14(5):697-710.
8. Baldwin DS, Woods R, Lawson R, et al. Efficacy of drug treatments for generalised anxiety disorder: Systematic review and meta analysis. BMJ. 2011;342:d1199.
9. Bandelow B, Sher L, Bunevicius R, et al; WFSBP Task Force on Anxiety Disorders, OCD and PTSD. Guidelines for the pharmacological treatment of anxiety disorders, obsessive compulsive disorder and posttraumatic stress disorder in primary care. IntJPsychiatry din Pract. 2012;16(2):77
10. Reinhold JA, Mandos LA, Rickels K, et al. Pharmacological treatment of generalized anxiety disorder. Expert Opin Pharmacother. 2011;12(16):2457-2467.
11. Kapczinski F, Lima MS, Souza JS, et al. Antidepressants for generalized anxiety disorder. Cochrane Database Syst Rev. 2003;(2) :CD003592.
12. de Bodinat C, Guardiola Lemaitre B, Moca?r E, et al. Agomelatine, the first melatonergic antidepressant: Discovery, characterization and development. Nat Rev DrugDiscov. 2010;9(8):628-642.
13. Montgomery SA, Kennedy SH, Burrows GD, et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: A randomized, double blind, placebo controlled discontinuation study. mt din Psychopharmacol. 2004;19(5):271-280.
14. Kasper S, Hajak G, Wulff K, et al. Efficacy of the novel antidepressant agomelatine on the circadian rest activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: A randomized, double blind comparison with sertraline. I din Psychiatry. 2010;71(2):109-120.
15. Kennedy SH, Rizvi SJ. Agomelatine in the treatment of major depressive disorder: Potential for clinical effectiveness. CNS Drugs. 2010;24(6):479-499.
16. Stein DJ, Ahokas AA, de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder: A randomized, double blind, placebo controlled study. I din Psychopharmacol. 2008;28(5) :561-566.
17. Stein DJ, Ahokas A, Albarran Severo C, et al. Agomelatine prevents relapse in generalised anxiety disorder: A 6 month placebo controlled discontinuation study. I din Psychiatry. 2012;73(7):1002-1008.
18. Baldwin DS, Huusom AK, Maehlum E. Escitalopram and paroxetine in the treatment of generalised anxiety disorder: Randomised, placebo controlled, double blind study. Br I Psychiatry. 2006;189(3):264-272.
19. Davidson JR, Bose A, Korotzer A, et al. Escitalopram in the treatment of generalized anxiety disorder: Double blind, placebo controlled, flexible dose study. Depress Anxiety. 2004;19(4):234-240.
20. Goodman WK, Bose A, Wang Q. Treatment of generalized anxiety disorder with escitalopram: Pooled results from double blind, placebo controlled trials.JAffectDisord. 2005;87(2-3):161-167.
21. Stein DJ, Andersen HF, Goodman WK. Escitalopram for the treatment of GAD: Efficacy across different subgroups and outcomes. Ann din Psychiatry. 2005;17(2):71
22. Good Clinical Practice ICH E6. US Dept of Health and Human Services, Food and Drug Administration; 1996.
23. World Medical Association. World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. Amended. Seoul: 2008.
24. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini International Neuropsychiatric Interview (MINI.): The development and validation of a structured diagnostic psychiatric interview for DSM IV and IdD 10. I dIm Psychiatry. 1998;59(suppl 20):22-33, quiz 34-57.
25. Hamilton M. The assessment of anxiety states by rating. BrfMedPsychol. 1959;32(1):50-55.
26. Zigmond AS, Snaith 1W. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361-370.
27. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. BrfPsychiatry. 1979;134(4):382-389.
28. Guy W ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976:217-222.
29. Parrott AC, Hindmarch I. The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations a review. Psychopharmacology (Berl). 1980;71(2):173-179.
30. Sheehan DV, Harnett Sheehan K, Raj BA. The measurement of disability. mt dIm Psychopharmacol. 1996;11(suppl 3):89-95.
31. Stein DJ, Picarel Blanchot F, Kennedy SH. Efficacy of the novel antidepressant agomelatine on anxiety symptoms in major depression. Hum Psychopharmacol. 2013;28(2):151-159.
32. Jackson JL, Houston JS, Hanling SR, et al. Clinical predictors of mental disorders among medical outpatients. Arch Intern Med. 2001;161(6): 875-879.
33. Andrews G, Slade T. The classification of anxiety disorders in lCD 10 and DSM IV: A concordance analysis. Psychopathology. 2002;35(2-3):100-106.
34. Papadimitriou GN, Linkowski P. Sleep disturbance in anxiety disorders. mt Rev Psychiatry. 2005;17(4):229-236.
35. Stein DJ, Lopez AG. Effects of escitalopram on sleep problems in patients with major depression or generalized anxiety disorder. Adv Ther. 2011;28(11):1021-1037.
36. Hickie IB, Rogers NL. Novel melatonin based therapies: Potential advances in the treatment of major depression. Lancet. 2011;378(9791):621-631.
37. Hoertel N, Le Strat Y, Blanco C, et al. Generalizability of clinical trial results for generalized anxiety disorder to community samples. Depress Anxiety. 2012;29(7):614-620.
38. Feltner DE, Crockatt JG, Dubovsky SJ, et al. A randomized, double blind, placebo controlled, fixed dose, multicenter study of pregabalin in patients with generalized anxiety disorder. I dIm Psychopharmacol. 2003;23(3): 240-249.
39. Hartford J, Kornstein S, Liebowitz M, et al. Duloxetine as an SNRI treatment for generalized anxiety disorder: Results from a placebo and active controlled trial. mnt dIm Psychopharmacol. 2007;22(3):167-174.
40. Montgomery SA, Tobias K, Zornberg GL, et al. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: A 6 week, multicenter, randomized, double blind, placebo controlled comparison of pregabalin and venlafaxine. I dIm Psychiatry. 2006;67(5):771-782.